Citadel Advisors’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $602K | Sell |
195,600
-382,900
| -66% | -$1.63M | ﹤0.01% | 8841 |
|
|
2025
Q4 | $2.09M | Buy |
578,500
+211,700
| +58% | +$923K | ﹤0.01% | 5825 |
|
|
2025
Q3 | $1.38M | Sell |
366,800
-519,600
| -59% | -$2.01M | ﹤0.01% | 6833 |
|
|
2025
Q2 | $3.43M | Buy |
886,400
+634,000
| +251% | +$3.43M | ﹤0.01% | 4747 |
|
|
2025
Q1 | $1.26M | Sell |
252,400
-108,400
| -30% | -$687K | ﹤0.01% | 6437 |
|
|
2024
Q4 | $2.6M | Buy |
360,800
+144,800
| +67% | +$1.11M | ﹤0.01% | 5096 |
|
|
2024
Q3 | $1.33M | Buy |
216,000
+69,300
| +47% | +$469K | ﹤0.01% | 6289 |
|
|
2024
Q2 | $976K | Sell |
146,700
-102,600
| -41% | -$757K | ﹤0.01% | 6623 |
|
|
2024
Q1 | $2.54M | Sell |
249,300
-34,100
| -12% | -$347K | ﹤0.01% | 5065 |
|
|
2023
Q4 | $3.19M | Buy |
283,400
+164,600
| +139% | +$687K | ﹤0.01% | 4533 |
|
|
2023
Q3 | $309K | Buy |
118,800
+34,200
| +40% | +$98.1K | ﹤0.01% | 9106 |
|
|
2023
Q2 | $299K | Sell |
84,600
-181,900
| -68% | -$817K | ﹤0.01% | 9063 |
|
|
2023
Q1 | $1.12M | Buy |
266,500
+172,100
| +182% | +$2.04M | ﹤0.01% | 6520 |
|
|
2022
Q4 | $1.55M | Sell |
94,400
-153,600
| -62% | -$1.73M | ﹤0.01% | 5971 |
|
|
2022
Q3 | $3.17M | Buy |
248,000
+220,100
| +789% | +$3.25M | ﹤0.01% | 4700 |
|
|
2022
Q2 | $326K | Sell |
27,900
-4,200
| -13% | -$25.9K | ﹤0.01% | 9618 |
|
|
2022
Q1 | $195K | Sell |
32,100
-34,400
| -52% | -$253K | ﹤0.01% | 11572 |
|
|
2021
Q4 | $609K | Sell |
66,500
-117,000
| -64% | -$1.24M | ﹤0.01% | 9193 |
|
|
2021
Q3 | $2.08M | Sell |
183,500
-93,300
| -34% | -$1.13M | ﹤0.01% | 6256 |
|
|
2021
Q2 | $2.73M | Buy |
276,800
+173,200
| +167% | +$2.37M | ﹤0.01% | 5839 |
|
|
2021
Q1 | $1.46M | Sell |
103,600
-11,300
| -10% | -$183K | ﹤0.01% | 7165 |
|
|
2020
Q4 | $1.3M | Buy |
114,900
+29,600
| +35% | +$349K | ﹤0.01% | 6243 |
|
|
2020
Q3 | $1.13M | Buy |
85,300
+50,800
| +147% | +$1.02M | ﹤0.01% | 5830 |
|
|
2020
Q2 | $369K | Buy |
34,500
+21,000
| +156% | +$115K | ﹤0.01% | 7572 |
|
|
2020
Q1 | $43K | Buy |
+13,500
| New | +$31K | ﹤0.01% | 9093 |
|
|
2019
Q2 | – | Sell |
-15,200
| Closed | -$44K | – | 9112 |
|
|
2019
Q1 | $44K | Buy |
+15,200
| New | +$45.3K | ﹤0.01% | 8869 |
|
|
2016
Q3 | – | Sell |
-40
| Closed | -$30K | – | 7189 |
|
|
2016
Q2 | $30K | Sell |
40
-34
| -46% | -$23.3K | ﹤0.01% | 6518 |
|
|
2016
Q1 | $42K | Buy |
+74
| New | +$37.9K | ﹤0.01% | 6287 |
|
|
2015
Q1 | – | Sell |
-25
| Closed | -$14K | – | 8484 |
|
|
2014
Q4 | $14K | Sell |
25
-21
| -46% | -$10.8K | ﹤0.01% | 8006 |
|
|
2014
Q3 | $24K | Buy |
46
+24
| +109% | +$12.5K | ﹤0.01% | 7320 |
|
|
2014
Q2 | $9K | Buy |
22
+17
| +340% | +$7.69K | ﹤0.01% | 7594 |
|
|
2014
Q1 | $3K | Buy |
+5
| New | +$2.92K | ﹤0.01% | 7696 |
|
|
2013
Q3 | – | Sell |
-7
| Closed | -$3K | – | 6697 |
|
|
2013
Q2 | $3K | Buy |
+7
| New | +$3.47K | ﹤0.01% | 6382 |
|
Other funds holding ALT
VCM
VPM
N
Citadel Advisors's ALT Position: Q1 2026 in Review
Citadel Advisors reduced its Altimmune (ALT) stake by 66% in Q1 2026, selling an estimated $3.77M and leaving 448,873 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #6905.
Citadel Advisors first reported a position in ALT in Q1 2014 and has held it in 35 quarters since. The position peaked at $19.1M in Q4 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.
- Citadel Advisors held 448,873 shares of Altimmune worth $1.38M as of Q1 2026.
- Citadel Advisors sold 889,054 Altimmune shares in Q1 2026, an estimated $3.77M.
- Altimmune made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6905 holding.
- Citadel Advisors first reported a position in Altimmune in Q1 2014 and has held it in 35 quarters since.
- Citadel Advisors's Altimmune position peaked at $19.1M in Q4 2022.
- 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.